Genprex, Inc. (GNPX)
Largest Insider Buys in Sector
GNPX Stock Price History Chart
GNPX Stock Performance
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Insider Activity of Genprex, Inc.
Over the last 12 months, insiders at Genprex, Inc. have bought $0 and sold $0 worth of Genprex, Inc. stock.
On average, over the past 5 years, insiders at Genprex, Inc. have bought $51,887 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $21,478 was made by VACZY CATHERINE M (EVP GC Chief Strategy Officer) on 2023‑04‑21.
List of Insider Buy and Sell Transactions, Genprex, Inc.
| 2023-04-21 | EVP GC Chief Strategy Officer | 20,000 0.0426% | $1.07 | $21,478 | -31.68% | |||
| 2023-04-21 | Chairman, President and CEO | 19,000 0.0398% | $1.05 | $20,045 | -31.68% | |||
| 2021-04-05 | director | 15,000 0.0313% | $4.15 | $62,250 | -37.14% | |||
| 2019-09-05 | Chief Executive Officer | 1,800 0.0116% | $0.89 | $1,595 | +158.62% | |||
| 2018-07-30 | President & COO | 500 0.0038% | $3.40 | $1,700 | -47.75% | |||
| 2018-03-29 | 10 percent owner | 40,000 0.3625% | $5.00 | $200,000 | -53.19% | |||
| 2018-03-29 | Chief Executive Officer | 10,000 0.0906% | $5.00 | $50,000 | -53.19% | |||
| 2018-03-29 | 10 percent owner | 50,000 0.4531% | $5.00 | $250,000 | -53.19% |
Insider Historical Profitability
| ROTH JACK A | 10 percent owner | 1338999 15.738% | $0.93 | 1 | 0 | <0.0001% |
| VACZY CATHERINE M | EVP GC Chief Strategy Officer | 265000 3.1147% | $0.93 | 1 | 0 | <0.0001% |
| Nance Christy M. | 10 percent owner | 50000 0.5877% | $0.93 | 1 | 0 | <0.0001% |
| Varner John Rodney | Chairman, President and CEO | 20800 0.2445% | $0.93 | 3 | 0 | +24.58% |
| LONGNECKER BRENT M | director | 15000 0.1763% | $0.93 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Armistice Capital Llc | $291,647.00 | 4.66 | 97,868 | New | +$291,647.00 | <0.01 | |
| The Vanguard Group | $45,639.00 | 0.73 | 15,315 | -99.16% | -$5.4M | <0.0001 | |
| Geode Capital Management | $35,743.00 | 0.57 | 11,991 | -97.57% | -$1.43M | <0.0001 | |
| BlackRock | $33,954.00 | 0.54 | 11,394 | -97.5% | -$1.32M | <0.0001 | |
| Tower Research Capital | $8,240.00 | 0.13 | 2,765 | -80.38% | -$33,761.65 | <0.0001 |